UBRELVY® PHARMACOLOGIC CHARACTERISTICS
PHARMACOKINETIC PROFILE
UBRELVY is an immediate-release tablet that is rapidly dissolved and pharmacologically active within minutes1,2
9 to 11 minutes:
time to pharmacologically active concentration with UBRELVY 100 mg and UBRELVY 50 mg, respectively1,3*
1.5 hours:
time to peak plasma concentrations4
5 to 7 hours:
elimination half-life4
The clinical significance of these data is not known.
UBRELVY displays dose-proportional pharmacokinetics within the recommended dose range.4
*Time to pharmacologically active concentration with UBRELVY 50 mg based on the inhibition of human capsaicin-induced dermal vasodilation model, a pharmacodynamic measure of CGRP blockade, EC90=13 ng/mL.1
UBRELVY WORKS DIFFERENTLY THAN
OLDER ACUTE TREATMENTS5
UBRELVY DIRECTLY BLOCKS CGRP6
UBRELVY stops calcitonin gene-related protein (CGRP) from binding to its receptor on the postsynaptic neuron, thereby blocking migraine pain signaling.4
UBRELVY IS NOT KNOWN TO CONSTRICT BLOOD VESSELS
when acting on the migraine disease pathway
The clinical significance of this mechanism of action is unknown.
See Important Safety Information for Warnings and Precautions.
Up next: Help enable access to UBRELVY
